A Need for Alternatives $54.898M Market Capitalization ERYTECH Pharma (ERYP.Q) announced today that the Company has sold its US manufacturing facility to Catalent, a leading contract development and manufacturing organization…
ERYP.Q
ERYTECH Pharma (ERYP.Q) announced today that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who…